Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 31-Jan-18 9:59 AM View:  | Masterson Nola E Director | Repros Therapeutics Inc. (RPRX) | 31-Jan-18 | Disposition | 27,779 | $0.67 | $18,611.90 | (100%) 27.78K to 0 | < 1% |
| 31-Jan-18 10:01 AM View: | Ramasastry Saira Director | Repros Therapeutics Inc. (RPRX) | 31-Jan-18 | Disposition | 27,779 | $0.67 | $18,611.90 | (100%) 27.78K to 0 | < 1% |
| 31-Jan-18 10:02 AM View: | Fourteau Patrick Director | Repros Therapeutics Inc. (RPRX) | 31-Jan-18 | Disposition | 27,779 | $0.67 | $18,611.90 | (100%) 27.78K to 0 | < 1% |
| 31-Jan-18 10:03 AM View: | Wyllie Michael Director | Repros Therapeutics Inc. (RPRX) | 31-Jan-18 | Disposition | 27,779 | $0.67 | $18,611.90 | (100%) 27.78K to 0 | < 1% |
| 31-Jan-18 9:57 AM View: | Cain Daniel F Director | Repros Therapeutics Inc. (RPRX) | 31-Jan-18 | Disposition | 27,779 | $0.67 | $18,611.90 | (100%) 27.78K to 0 | < 1% |
| 31-Jan-18 10:03 AM View: | Wyllie Michael Director | Repros Therapeutics Inc. (RPRX) | 29-Jan-18 | Disposition (change in control) | 21,580 | $0.67 | $14,458.60 | (44%) 49.36K to 27.78K | < 1% |
| 31-Jan-18 9:57 AM View: | Cain Daniel F Director | Repros Therapeutics Inc. (RPRX) | 29-Jan-18 | Disposition (change in control) | 23,221 | $0.67 | $15,558.10 | (46%) 51.0K to 27.78K | < 1% |
| 31-Jan-18 10:01 AM View: | Ramasastry Saira Director | Repros Therapeutics Inc. (RPRX) | 29-Jan-18 | Disposition (change in control) | 12,221 | $0.67 | $8,188.07 | (31%) 40.0K to 27.78K | < 1% |
| 31-Jan-18 10:02 AM View: | Fourteau Patrick Director | Repros Therapeutics Inc. (RPRX) | 29-Jan-18 | Disposition (change in control) | 12,221 | $0.67 | $8,188.07 | (31%) 40.0K to 27.78K | < 1% |
| 31-Jan-18 9:59 AM View: | Masterson Nola E Director | Repros Therapeutics Inc. (RPRX) | 29-Jan-18 | Disposition (change in control) | 12,221 | $0.67 | $8,188.07 | (31%) 40.0K to 27.78K | < 1% |
| 31-Jan-18 9:54 AM View: | Anderson Katherine Chief Financial Officer | Repros Therapeutics Inc. (RPRX) | 29-Jan-18 | Disposition (change in control) | 83,875 | $0.67 | $56,196.20 | (100%) 83.88K to 0 | < 1% |
| 05-Jul-17 4:00 PM View: | Anderson Katherine Chief Financial Officer | Repros Therapeutics Inc. (RPRX) | 03-Jul-17 | Grant | 10,000 | -- | -- | 14% 73.88K to 83.88K | |
| 02-Jun-17 4:00 PM View: | Anderson Katherine Chief Financial Officer | Repros Therapeutics Inc. (RPRX) | 01-Jun-17 | Grant | 10,000 | -- | -- | 16% 63.88K to 73.88K | |
| 01-May-17 4:01 PM View: | Anderson Katherine Chief Financial Officer | Repros Therapeutics Inc. (RPRX) | 01-May-17 | Grant | 10,000 | -- | -- | 19% 53.88K to 63.88K | |
| 04-Apr-17 4:13 PM View: | Anderson Katherine Chief Financial Officer | Repros Therapeutics Inc. (RPRX) | 03-Apr-17 | Grant | 10,000 | -- | -- | 23% 43.88K to 53.88K | |
| 02-Mar-17 4:26 PM View: | Anderson Katherine Chief Financial Officer | Repros Therapeutics Inc. (RPRX) | 01-Mar-17 | Grant | 10,000 | -- | -- | 30% 33.88K to 43.88K | |
| 15-Feb-17 4:35 PM View: | Wyllie Michael Director | Repros Therapeutics Inc. (RPRX) | 13-Feb-17 | Grant | 40,000 | -- | -- | 427% 9.36K to 49.36K | |
| 15-Feb-17 4:30 PM View: | Cain Daniel F Director | Repros Therapeutics Inc. (RPRX) | 13-Feb-17 | Grant | 40,000 | -- | -- | 364% 11.0K to 51.0K | |
| 15-Feb-17 4:28 PM View: | Masterson Nola E Director | Repros Therapeutics Inc. (RPRX) | 13-Feb-17 | Grant | 40,000 | -- | -- | 100% 0 to 40.0K | |
| 15-Feb-17 4:32 PM View: | Ramasastry Saira Director | Repros Therapeutics Inc. (RPRX) | 13-Feb-17 | Grant | 40,000 | -- | -- | 100% 0 to 40.0K | |
| 15-Feb-17 4:26 PM View: | Fourteau Patrick Director | Repros Therapeutics Inc. (RPRX) | 13-Feb-17 | Grant | 40,000 | -- | -- | 100% 0 to 40.0K | |
| 03-Feb-17 4:40 PM View: | Anderson Katherine Chief Financial Officer | Repros Therapeutics Inc. (RPRX) | 01-Feb-17 | Grant | 10,000 | -- | -- | 42% 23.88K to 33.88K | |
| 09-Dec-16 5:13 PM View: | Podolski Joseph President and CEO Director | Repros Therapeutics Inc. (RPRX) | 09-Dec-16 | Market Purchase | 20,000 | $1.60 | $32,000.00 | 23% 87.42K to 107.42K | (61%) |
| 23-Nov-16 4:07 PM View: | Masterson Nola E Director | Repros Therapeutics Inc. (RPRX) | 21-Nov-16 | Market Sale | 3,305 | $1.95 | $6,444.75 | (100%) 3.31K to 0 | 68% |
| 19-Feb-16 4:06 PM View: | Podolski Joseph President and CEO Director | Repros Therapeutics Inc. (RPRX) | 18-Feb-16 | Market Purchase | 10,000 | $0.93 | $9,300.00 | 13% 77.42K to 87.42K | (33%) |
| 28-Jan-16 4:12 PM View: | Anderson Katherine Chief Financial Officer | Repros Therapeutics Inc. (RPRX) | 27-Jan-16 | Market Purchase | 12,000 | $1.08 | $12,960.00 | 101% 11.88K to 23.88K | (42%) |
| 28-Jan-16 4:12 PM View: | Wernicke J. F. Chief Medical Officer | Repros Therapeutics Inc. (RPRX) | 25-Jan-16 | Market Purchase | 10,000 | $1.11 | $11,125.80 | 100% 0 to 10.0K | (44%) |
| 07-Jan-16 4:44 PM View: | Podolski Joseph President and CEO Director | Repros Therapeutics Inc. (RPRX) | 07-Jan-16 | Market Purchase | 3,500 | $1.14 | $3,990.00 | 5% 73.92K to 77.42K | (45%) |
| 07-Jan-16 4:44 PM View: | Podolski Joseph President and CEO Director | Repros Therapeutics Inc. (RPRX) | 06-Jan-16 | Market Purchase | 8,177 | $1.20 | $9,804.22 | 12% 65.75K to 73.92K | (48%) |
| 12-Nov-14 5:19 PM View: | Anderson Katherine Chief Financial Officer | Repros Therapeutics Inc. (RPRX) | 12-Nov-14 | Market Purchase | 3,500 | $9.41 | $32,951.80 | 42% 8.38K to 11.88K | (93%) |
| 12-Nov-14 5:17 PM View: | Podolski Joseph President and CEO Director | Repros Therapeutics Inc. (RPRX) | 12-Nov-14 | Market Purchase | 4,700 | $9.42 | $44,274.50 | 8% 61.05K to 65.75K | (93%) |
| 17-Sep-14 9:43 AM View: | Masterson Nola E Director | Repros Therapeutics Inc. (RPRX) | 15-Sep-14 | Market Purchase | 200 | $14.34 | $2,868.00 | 6% 3.1K to 3.31K | (96%) |
| 14-Aug-14 3:53 PM View: | Podolski Joseph President and CEO Director | Repros Therapeutics Inc. (RPRX) | 14-Aug-14 | Market Purchase | 2,100 | $13.91 | $29,211.00 | 4% 58.95K to 61.05K | (96%) |
| 14-Aug-14 3:51 PM View: | Anderson Katherine Chief Financial Officer | Repros Therapeutics Inc. (RPRX) | 14-Aug-14 | Market Purchase | 2,000 | $13.85 | $27,700.00 | 31% 6.38K to 8.38K | (95%) |
| 10-Jan-14 4:52 PM View: | Cain Daniel F Director | Repros Therapeutics Inc. (RPRX) | 10-Jan-14 | Option Exercise | 10,000 | $9.60 | $96,000.00 | 1000% 1.0K to 11.0K | |
| 14-Nov-13 11:20 AM View: | Cain Daniel F Director | Repros Therapeutics Inc. (RPRX) | 12-Nov-13 | Market Purchase | 500 | $14.97 | $7,485.00 | 100% 0.5K to 1.0K | (96%) |
| 25-Oct-13 4:29 PM View: | Anderson Katherine Chief Financial Officer | Repros Therapeutics Inc. (RPRX) | 25-Oct-13 | Market Purchase | 1,000 | $17.90 | $17,900.00 | 19% 5.38K to 6.38K | (97%) |
| 25-Oct-13 4:32 PM View: | Podolski Joseph President and CEO Director | Repros Therapeutics Inc. (RPRX) | 25-Oct-13 | Market Purchase | 3,000 | $18.03 | $54,102.00 | 5% 55.95K to 58.95K | (97%) |
| 11-Oct-13 11:52 AM View: | Anderson Katherine Chief Financial Officer | Repros Therapeutics Inc. (RPRX) | 10-Oct-13 | Market Purchase | 1,000 | $23.77 | $23,770.00 | 23% 4.38K to 5.38K | (97%) |
| 20-Mar-13 8:20 AM View: | Perceptive Advisors LLC 10% Owner | Repros Therapeutics Inc. (RPRX) | 15-Mar-13 | Exercise (in-the money or at-the-money) | 2,050,000 | $12.32 | $25,250,000.00 | (72%) 2.86M to 812.56K | |
| 04-Feb-13 12:13 PM View: | Anderson Katherine Chief Financial Officer | Repros Therapeutics Inc. (RPRX) | 01-Feb-13 | Market Purchase | 1,000 | $11.89 | $11,890.00 | 30% 3.38K to 4.38K | (95%) |
| 29-Oct-12 5:03 PM View: | Wyllie Michael Director | Repros Therapeutics Inc. (RPRX) | 29-Oct-12 | Payment of Exercise | 1,068 | $13.83 | $14,770.40 | (10%) 10.43K to 9.36K | 95% |
| 29-Oct-12 5:03 PM View: | Wyllie Michael Director | Repros Therapeutics Inc. (RPRX) | 29-Oct-12 | Option Exercise | 3,333 | $4.43 | $14,765.20 | 47% 7.09K to 10.43K | |
| 13-Sep-12 5:49 PM View: | Wyllie Michael Director | Repros Therapeutics Inc. (RPRX) | 12-Sep-12 | Option Exercise | 9,999 | $4.43 | $44,295.60 | 100% 0 to 10.0K | |
| 13-Sep-12 6:16 PM View: | Masterson Nola E Director | Repros Therapeutics Inc. (RPRX) | 12-Sep-12 | Payment of Exercise | 10,645 | $15.27 | $162,549.00 | (76%) 14.0K to 3.35K | 96% |
| 13-Sep-12 5:49 PM View: | Wyllie Michael Director | Repros Therapeutics Inc. (RPRX) | 12-Sep-12 | Payment of Exercise | 2,905 | $15.25 | $44,301.20 | (29%) 10.0K to 7.09K | 96% |
| 13-Sep-12 6:16 PM View: | Masterson Nola E Director | Repros Therapeutics Inc. (RPRX) | 12-Sep-12 | Option Exercise | 11,250 | $14.45 | $162,550.00 | 409% 2.75K to 14.0K | (96%) |
| 15-May-12 2:11 PM View: | Perceptive Advisors LLC 10% Owner | Repros Therapeutics Inc. (RPRX) | 14-May-12 | Market Purchase | 59,500 | $7.38 | $439,283.00 | 2% 2.8M to 2.86M | (92%) |
| 14-May-12 2:19 PM View: | Perceptive Advisors LLC 10% Owner | Repros Therapeutics Inc. (RPRX) | 11-May-12 | Market Purchase | 170,000 | $6.35 | $1,079,840.00 | 6% 2.63M to 2.8M | (90%) |
| 11-May-12 3:22 PM View: | Perceptive Advisors LLC 10% Owner | Repros Therapeutics Inc. (RPRX) | 10-May-12 | Market Purchase | 325,000 | $4.82 | $1,566,100.00 | 14% 2.31M to 2.63M | (87%) |
